Abstract 2061P
Background
Patients’ concerns have become more complicated, while the advancements in cancer treatments have improved clinical outcomes. This study aims to comprehensively explore the concerns of cancer patients and to elucidate their interrelationships.
Methods
A fact-finding survey was conducted with 300 cancer patients (male; 127, female; 173) using a 74-item questionnaire. The questionnaire included comprehensive items (rated from 0 [none] to 3 [severe]) related to the concerns of cancer patients. Correlation network analysis was performed to visualize the association between the patients’ concerns. Degree centrality was used to assess network centrality, and the Girvan–Newman algorithm was used to detect communities.
Results
Cancer types were as follows: breast cancer (n=84), gastrointestinal cancer (n=82), urologic cancer (n=52), cholangiopancreatic cancer (n=44), gynecologic cancer (n=20), and others (n=18). The mean overall score was significantly higher in females than in males (30.4 vs. 22.5, p<0.01). The most frequent concerns were physical decline (81.7 %), fatigue (80.5 %), muscle weakness in the limbs (65.9 %). In the overall network, the concerns with the highest centrality score were muscle weakness in the limbs (0.151), nutritional management (0.123) and fatigue (0.082). The network was classified into three communities: 1) physical decline, including 21 items such as muscle weakness, nutritional management, and fatigue; 2) changes in appearance, including 8 items such as pigmentation and hair loss; 3) social support, including 11 items such as employment and finances. The network analysis by gender showed that the highest centered item was sex life (0.123) in men, and depression (0.137) and anxiety (0.110) in women.
Conclusions
This study illustrated that cancer-related fatigue and weakness were the most frequently and numerous interrelated concerns that plagued patients with cancer. Furthermore, they formed a wide-ranging network with other concerns. Our study also showed that the structure of the network differed between the sexes. A multidisciplinary approach may be necessary to comprehensively solve interrelated patient concerns.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
Y. Miura: Financial Interests, Personal, Invited Speaker: Takeda, MSD, Bristol Myers Squibb, Ono Pharmaceutical, Merck BioPharma, Eisai, Astellas Pharma; Financial Interests, Institutional, Local PI: Ono Pharmaceutical, MSD. All other authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06